InflaRx N.V. (IFRX)
InflaRx N.V. (IFRX) Stock Price, Analysis & Data
| Bid | 1.48 |
| Market Cap | 296.06M |
| Revenue (ttm) | -10.1K |
| Net Income (ttm) | -39.14M |
| Beta | n/a |
| EPS (ttm) | -0.58 |
| PE Ratio (ttm) | n/a |
| Forward PE | -5.03 |
| P/B (ttm) | 3.41 |
| P/S (ttm) | -29309.84 |
| Earnings Date | Nov 9, 2026 |
| Ask | 2.49 |
| Volume | 1,569,704 |
| Avg. Volume (20D) | 1,170,274 |
| Open | 1.99 |
| Previous Close | 2.00 |
| Day's Range | 1.93 - 2.06 |
| 52-Week Range | 0.78 - 2.95 |
| Analyst | Strong Buy |
| Price Target | 8.49 (322.39%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About IFRX
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering f...
Financial Performance
In 2025, InflaRx's revenue was 29.33K, a decrease of -82.31% compared to the previous year's 165.79K. Earnings were -45.63M, a decrease of -0.93%.
Financial StatementsAnalyst Forecast
According to 8 analyst ratings, the average rating for IFRX stock is "Strong Buy". The 12-month stock price forecast is 8.49, which is upside of 322.39% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
